Apellis Pharmaceuticals, Inc. Common Stock (APLS)
Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing eye and immune system therapies. Founded in 2009, it specializes in complement immunology to create treatments for diseases such as geographic atrophy, paroxysmal nocturnal hemoglobinuria, and other immune-related conditions. The company leverages its innovative complement inhibition platform to address unmet medical needs in both ophthalmology and systemic diseases.
Company News
Apellis Pharmaceuticals presented one-year clinical data for EMPAVELI, demonstrating sustained proteinuria reduction and kidney function stabilization in patients with rare kidney diseases C3G and IC-MPGN, with indirect comparisons suggesting superiority over competitor iptacopan.
Apellis Pharmaceuticals reported a Q1 revenue decline and wider net loss, missing analyst expectations. However, the company continues to develop its drugs Syfovre and Empaveli for new indications, with an FDA decision on Empaveli expected in July.
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
Throughout the last three months, 14 analysts have evaluated Apellis Pharmaceuticals (NASDAQ:APLS), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indiffe...